Health Care & Life Sciences » Biotechnology | Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
60.56 M
Public Float
31.46 M
Karyopharm Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$3.44
Market Cap
$536.21 M
Shares Outstanding
60.86 M
Public Float
53.35 M

Profile

Address
85 Wells Avenue
Newton Massachusetts 02459
United States
Employees -
Website http://www.karyopharm.com
Updated 07/08/2019
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A.

Financials

View All

Mansoor Raza Mirza
Independent Director
Michael F. Falvey
Chief Financial Officer, Treasurer & Executive VP